Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

thyroid cancer

This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

metastatic RET-mutant medullary thyroid cancer and advanced or metastatic RET fusion-positive thyroid cancer. ... Although RET activating fusions and mutations are only observed in a small number of cancer patients – around 1-2% in NSCLC and 10-20% in

Latest news

  • Roche pays $775m upfront to access Blueprint’s RET programme Roche pays $775m upfront to access Blueprint’s RET programme

    Administration (FDA) for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. ... Although RET activating fusions and mutations are only

  • Exelixis bounces back with new prostate cancer data Exelixis bounces back with new prostate cancer data

    Exelixis previously attempted to tackle prostate cancer with cabozantinib back in 2014, but the drug was unable to show any survival benefit on its own. ... Cabozantinib, a c-MET and VEGFR2 inhibitor, is already approved under the brand name Cometriq as

  • Lilly will aim for one $1bn-$5bn deal per quarter in 2020 Lilly will aim for one $1bn-$5bn deal per quarter in 2020

    Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in phase 3 trials for non-small cell lung cancer and medullary thyroid cancer.

  • RET rivals Loxo and Blueprint face off with early-stage data RET rivals Loxo and Blueprint face off with early-stage data

    with BLU-667 for at least 24 weeks, and 49% across all patients with that type of cancer. ... Existing treatment of medullary and papillary thyroid cancer with multi-kinase inhibitors is limited by frequent dose modifications or interruptions due to

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung ... National Cancer Institute (NCI) in the US, the

More from news
Approximately 9 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and

  • Pharma deals during August 2013 Pharma deals during August 2013

    In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “holy

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Quick links